Stock Market Reviews

MNOV (MediciNova, Inc.) News

Get the latest news, insights, and market updates on MNOV (MediciNova, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
  Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patientsLA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces the publication of a new research article in the peer-reviewed Journal of Atherosclerosis and T
  Oct 30, 2025 - $MNOV
• MediciNova to Present at the LD Micro Main Event XIX Investor Conference
  LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will present a corporate overview at the LD Micro Main Event XIX Investor Conference. The conference is being held on October 19 – 22, 2025 at the Hote
  Oct 6, 2025 - $MNOV
• MediciNova concludes subject enrolment in trial of MN-166
  The COMBAT-ALS trial is a randomised, double-blind, placebo-controlled study with a 12-month blinded phase.
  Sep 23, 2025 - $MNOV
• MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
  ~Patient Recruitment Closed~LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in its Phase 2/3 clinical trial, COMBAT-ALS, evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 patients have been randomized across tw
  Sep 22, 2025 - $MNOV
• MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
  LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the Phase 2b/3 COMBAT clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients has been selected for a poster presentation at 36th International Symposium on ALS/MND to be held December 5-7, 2025 in San Diego
  Sep 16, 2025 - $MNOV
• MediciNova Provides Shareholder Update on Key Developments
  LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), provides a shareholder update recapping important developments for the Company. Standby Equity Purchase Agreement (SEPA) The Company reported the signing of a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of
  Sep 8, 2025 - $MNOV
• MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
  LA JOLLA, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, MD., Ph.D., President and CEO, and David H. Crean, PhD, Chief Business Officer will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 a
  Sep 3, 2025 - $MNOV
• MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
  LA JOLLA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it successfully achieved enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast). MN-166 is currently in development for the treatment of Amyotrophic Lateral Sclerosis (ALS). Dr. Yuichi Iwaki, MediciNova Pr
  Aug 26, 2025 - $MNOV
• MediciNova: Q2 Earnings Snapshot
  LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Thursday reported a loss of $3.3 million in its second quarter.
  Aug 14, 2025 - $MNOV
• 3 Penny Stocks With Market Caps Larger Than $10M To Watch
  As major U.S. indexes continue their upward trajectory, buoyed by strong corporate earnings and resilient economic data, investors are exploring various avenues for potential growth. Penny stocks, though an older term in the investment lexicon, remain relevant as a category that encompasses smaller or newer companies with lower price points. When these stocks are backed by robust financials and solid fundamentals, they can present unique opportunities for growth that might be overlooked in...
  Jul 31, 2025 - $MNOV